1.94
price down icon3.00%   -0.0599
pre-market  Pre-market:  1.94  
loading
22nd Century Group, Inc. stock is traded at $1.94, with a volume of 48,958. It is down -3.00% in the last 24 hours and down -37.22% over the past month. 22nd Century Group, Inc., a plant biotechnology company, provides technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and cannabinoids in hemp/cannabis plants through genetic engineering and plant breeding. It offers premium cigarettes under the RED SUN and MAGIC brands; and SPECTRUM, a line of research cigarettes for use in independent clinical studies. The company's products under development include BRAND A, a very low nicotine cigarette; X-22, a tobacco-based botanical medical product for use as an aid to smoking cessation; and BRAND B, a low-tar-to-nicotine ratio cigarette. In addition, it engages in contract manufacturing business for third-party branded tobacco products. The company has scientific collaborations with the University of Virginia and Anandia Laboratories, Inc. to develop proprietary hemp strains with less than 0.3% dry weight content of delta-9-tetrahydrocannabinol. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Williamsville, New York.
See More
Previous Close:
$1.9999
Open:
$1.91
24h Volume:
48,958
Relative Volume:
0.06
Market Cap:
$3.33M
Revenue:
$29.78M
Net Income/Loss:
$-39.94M
P/E Ratio:
-0.0313
EPS:
-61.9139
Net Cash Flow:
$-16.12M
1W Performance:
-6.28%
1M Performance:
-37.22%
6M Performance:
-95.80%
1Y Performance:
-99.33%
1-Day Range:
Value
$1.82
$2.03
1-Week Range:
Value
$1.79
$2.1489
52-Week Range:
Value
$1.75
$581.85

22nd Century Group, Inc. Stock (XXII) Company Profile

Name
Name
22nd Century Group, Inc.
Name
Phone
716-270-1523
Name
Address
8560 Main Street, Williamsville, NY
Name
Employee
79
Name
Twitter
@_xxiicentury
Name
Next Earnings Date
2024-12-12
Name
Latest SEC Filings
Name
XXII's Discussions on Twitter

Compare XXII with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
XXII
22nd Century Group, Inc.
1.94 3.33M 29.78M -39.94M -16.12M -61.91
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
502.92 129.14B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
680.61 74.41B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
581.21 35.31B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.75 31.30B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.57 27.35B 3.32B -860.46M -1.04B -8.32

22nd Century Group, Inc. Stock (XXII) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-21-22 Initiated Alliance Global Partners Buy
Jun-15-22 Initiated Craig Hallum Buy
Mar-08-22 Initiated ROTH Capital Buy
Jul-23-21 Initiated Cowen Outperform
Oct-16-17 Reiterated Chardan Capital Markets Buy
Aug-11-16 Reiterated Chardan Capital Markets Buy
View All

22nd Century Group, Inc. Stock (XXII) Latest News

pulisher
Mar 13, 2025

12 Cannabis Stocks to Buy Now in 2025 - MarketBeat

Mar 13, 2025
pulisher
Mar 11, 2025

22nd Century Announces First Partner VLN Agreement, New VLN Availability with Smoker Friendly - GlobeNewswire

Mar 11, 2025
pulisher
Mar 10, 2025

22nd Century Group expands VLN products with Smoker Friendly - Investing.com India

Mar 10, 2025
pulisher
Mar 08, 2025

XXII stock plunges to 52-week low, touches $3.03 amid market rout - MSN

Mar 08, 2025
pulisher
Mar 08, 2025

Weiss Ratings Reiterates “Sell (E)” Rating for 22nd Century Group (NASDAQ:XXII) - Defense World

Mar 08, 2025
pulisher
Mar 05, 2025

XXII stock plunges to 52-week low of $1.72 amid market challenges - Investing.com Australia

Mar 05, 2025
pulisher
Feb 28, 2025

22nd Century regains compliance with the Nasdaq - MSN

Feb 28, 2025
pulisher
Feb 24, 2025

XXII stock plunges to 52-week low of $2.98 amid market challenges - Investing.com Nigeria

Feb 24, 2025
pulisher
Feb 24, 2025

XXII stock plunges to 52-week low of $2.98 amid market challenges By Investing.com - Investing.com South Africa

Feb 24, 2025
pulisher
Feb 20, 2025

22nd Century Group (NASDAQ:XXII) Given “Sell (E+)” Rating at Weiss Ratings - Defense World

Feb 20, 2025
pulisher
Feb 19, 2025

Emerging Growth Research Releases New Initiation Report on the 22nd Century Group (XXII) - Newsfile

Feb 19, 2025
pulisher
Feb 16, 2025

22nd Century : FDA Lead Scientist Discusses 22nd Century’s SPECTRUM® Research Cigarettes in Public Webcast - Marketscreener.com

Feb 16, 2025
pulisher
Feb 14, 2025

22nd Century Group, Inc. (NASDAQ:XXII) Short Interest Down 63.8% in January - Defense World

Feb 14, 2025
pulisher
Feb 13, 2025

XXII stock plunges to 52-week low, touches $3.03 amid market rout By Investing.com - Investing.com South Africa

Feb 13, 2025
pulisher
Feb 06, 2025

22nd Century to Present at the Emerging Growth Conference on February 19, 2025 - Marketscreener.com

Feb 06, 2025
pulisher
Feb 06, 2025

Exclusive: 22nd Century Group Unveils Strategic Vision at Emerging Growth ConferenceCEO Takes Center Stage - StockTitan

Feb 06, 2025
pulisher
Feb 04, 2025

Weiss Ratings Reiterates Sell (E) Rating for 22nd Century Group (NASDAQ:XXII) - Defense World

Feb 04, 2025
pulisher
Feb 01, 2025

22nd Century files to sell 104,124 shares of common stock for holders - MSN

Feb 01, 2025
pulisher
Jan 31, 2025

22nd Century Sells Cannabis Operations - Tobacco Reporter

Jan 31, 2025
pulisher
Jan 31, 2025

Investors Buy 22nd Shares ‘Above Market’ - Tobacco Reporter

Jan 31, 2025
pulisher
Jan 31, 2025

22nd Century Launches Public Offering - Tobacco Reporter

Jan 31, 2025
pulisher
Jan 31, 2025

22nd Century Submits CBD Drug Master File - Tobacco Reporter

Jan 31, 2025
pulisher
Jan 31, 2025

22nd Century Eliminates $2.3 million of Debt - Tobacco Reporter

Jan 31, 2025
pulisher
Jan 31, 2025

22nd Century Reports Quarterly Results - Tobacco Reporter

Jan 31, 2025
pulisher
Jan 30, 2025

22nd Century Group (NASDAQ: XXII) and Smoker Friendly Forge New Agreement – Market - HPBL

Jan 30, 2025
pulisher
Jan 30, 2025

22nd Century Group (NASDAQ:XXII) Regains Compliance with Nasdaq Listing Rule 5550(a)(2) - Defense World

Jan 30, 2025
pulisher
Jan 28, 2025

22nd Century Regains Full Compliance with Nasdaq Continued Listing Standards - The Manila Times

Jan 28, 2025
pulisher
Jan 27, 2025

22nd Century Group Regains Nasdaq Compliance, Secures Exchange Listing - StockTitan

Jan 27, 2025
pulisher
Jan 19, 2025

22nd Century Group Announces Strategic Agreement with Smoker Friendly – Market - HPBL

Jan 19, 2025
pulisher
Jan 16, 2025

FDA Publishes Proposed New Tobacco Product Standard for Nicotine Yield, Citing VLN from 22nd Century as the Only Combustible Cigarette That Complies with the New Standard - The Manila Times

Jan 16, 2025
pulisher
Jan 15, 2025

22nd Century Group's VLN Cigarettes Already Meet FDA's Proposed Nicotine Reduction Standard - StockTitan

Jan 15, 2025
pulisher
Jan 15, 2025

22nd Century Group Resets Conversion Price in Senior Secured Credit Facility - Defense World

Jan 15, 2025
pulisher
Jan 14, 2025

Washington Post Story Featuring 22nd Century VLN Products Highlights Proposed FDA Reduced Nicotine Content Policy Could Initially Benefit An Estimated 13 Million Smokers - The Manila Times

Jan 14, 2025
pulisher
Jan 14, 2025

22nd Century's VLN Cigarettes Take Spotlight as FDA's Nicotine Reduction Plan Advances - StockTitan

Jan 14, 2025
pulisher
Jan 14, 2025

22nd Century Group Stock Rises On Proposed FDA Mandate On Nicotine Content: Retail's Extremely Bullish - MSN

Jan 14, 2025

22nd Century Group, Inc. Stock (XXII) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$75.07
price up icon 1.39%
$305.39
price down icon 0.55%
$19.19
price down icon 3.62%
$32.68
price down icon 0.52%
$97.47
price down icon 2.84%
biotechnology ONC
$254.57
price up icon 1.89%
Cap:     |  Volume (24h):